<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02590003</url>
  </required_header>
  <id_info>
    <org_study_id>1403013529</org_study_id>
    <nct_id>NCT02590003</nct_id>
  </id_info>
  <brief_title>Single Agent Versus Combination Chemotherapy to Treat High-risk Elderly With Non-small Cell Lung Cancer</brief_title>
  <official_title>A Randomized Phase II Trial of Combination Versus Single Agent Chemotherapy in High-risk Elderly Patients With Advanced Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will enroll elderly patients with advanced non-small cell lung cancer who are at&#xD;
      high risk of developing chemotherapy toxicity (side effects). Patients will receive treatment&#xD;
      with either a platinum-based doublet chemotherapy with carboplatin/nab-paclitaxel or single&#xD;
      agent nab-paclitaxel of chemotherapy. Response to treatment and treatment toxicity will be&#xD;
      compared in the two treatment groups to determine the best treatment strategy for this group&#xD;
      of patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this trial is to compare the treatment failure-free survival rate in&#xD;
      high-risk elderly patients, identified by geriatric assessment, treated with either a&#xD;
      platinum-based doublet chemotherapy with carboplatin/nab-paclitaxel or single agent&#xD;
      nab-paclitaxel in advanced non-small cell lung cancer. Treatment failure-free survival is the&#xD;
      most appropriate primary outcome as it captures excessive toxicity due to chemotherapy in&#xD;
      addition to death and disease progression.&#xD;
&#xD;
      The secondary objectives are to evaluate grade 3-5 toxicities, overall response rate,&#xD;
      progression free survival, symptom assessment, and overall survival between the two&#xD;
      randomization arms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Trial was stopped after non-response to treatment.&#xD;
  </why_stopped>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Failure-free Survival</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>start of treatment to disease progression/recurrence, up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>start of treatment to disease progression, up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 3-5 Adverse Events</measure>
    <time_frame>Up to week 13</time_frame>
    <description>Adverse events were characterized using Common Terminology Criteria for Adverse Events (CTCAE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom Assessment (Measured by FACT-L Symptom Assessment Scale)</measure>
    <time_frame>baseline</time_frame>
    <description>The FACT-L is measure of symptoms associated with lung cancer. The higher the score, the greater the symptoms. A maximum score of 136 could be obtained.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom Assessment (Measured by FACT-L Symptom Assessment Scale)</measure>
    <time_frame>week 6</time_frame>
    <description>The higher the score, the greater the symptoms. The FACT-L is measure of symptoms associated with lung cancer. The higher the score, the greater the symptoms. A maximum score of 136 could be obtained. Symptoms were measured following 2 21-day cycles of chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom Assessment (Measured by FACT-L Symptom Assessment Scale)</measure>
    <time_frame>week 12</time_frame>
    <description>The FACT-L is measure of symptoms associated with lung cancer. The higher the score, the greater the symptoms. Symptoms were measured following 4 21-day cycles of chemotherapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Carcinoma, Non-small Cell Lung</condition>
  <arm_group>
    <arm_group_label>Platinum-based doublet chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin AUC 5 30 minute infusion IV on day 1&#xD;
Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single agent chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>-Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <arm_group_label>Platinum-based doublet chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <arm_group_label>Platinum-based doublet chemotherapy</arm_group_label>
    <arm_group_label>Single agent chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient able and willing to comply with study procedures as per protocol, including&#xD;
             the geriatric assessment at the time of study enrollment.&#xD;
&#xD;
          2. Patient able to understand and willing to sign and date the written voluntary informed&#xD;
             consent form (ICF) at screening visit prior to any protocol-specific procedures.&#xD;
&#xD;
          3. Patients must have histological or cytological confirmed primary non-small cell lung&#xD;
             cancer (adenocarcinoma, large cell carcinoma, squamous, or unspecified). Disease must&#xD;
             be stage IV Non-Small Cell Lung Cancer (NSCLC). Disease may be either newly diagnosed&#xD;
             or recurrent after previous surgery and/or irradiation. Primary or metastatic site for&#xD;
             biopsy is allowed&#xD;
&#xD;
          4. Patients may have measurable or non-measurable disease documented by CT or MRI. The CT&#xD;
             from a combined PET/CT may be used to document only non-measurable disease. Measurable&#xD;
             disease must be assessed within 30 days prior to registration per response evaluation&#xD;
             criteria in solid tumors (RECIST) v1.1. Pleural effusions, ascites and laboratory&#xD;
             parameters are not acceptable as the only evidence of disease. Non- measurable disease&#xD;
             must be assessed within 30 days prior to registration. All disease must be assessed&#xD;
             and documented on the Baseline Tumor Assessment Form.&#xD;
&#xD;
          5. Prior chemotherapy for curative intent is permitted providing the cytotoxic&#xD;
             chemotherapy was completed ≥12 months prior to enrollment. Patients must have a CT or&#xD;
             MRI scan of the brain to evaluate for CNS disease within 30 days prior to&#xD;
             registration. Patient must not have brain metastases unless: (1) metastases have been&#xD;
             treated and have remained controlled for at least two weeks following treatment, AND&#xD;
             (2) patient has no residual neurological dysfunction off corticosteroids for at least&#xD;
             1 day. Any radiation therapy completed prior to chemotherapy, except gamma-knife&#xD;
             radiosurgery, 1 week prior to chemotherapy.&#xD;
&#xD;
          6. Age &gt;70 years of age at time of signing of the informed consent form.&#xD;
&#xD;
          7. Life expectancy of greater than 12 weeks.&#xD;
&#xD;
          8. ECOG performance status 0-2 (See Appendix A)&#xD;
&#xD;
          9. Patients must have a comprehensive geriatric assessment and chemotherapy toxicity&#xD;
             assessment score between 7-17 (See Appendix B, D)&#xD;
&#xD;
         10. Patients must have normal organ and marrow function as defined below:&#xD;
&#xD;
               -  Leukocytes &gt;3,000/mcL&#xD;
&#xD;
               -  ANC &gt; 1,500 cells/mm3Hemoglobin &gt; 9.0g/dL&#xD;
&#xD;
               -  Platelets &gt;100,000 cells/mm3&#xD;
&#xD;
               -  Total bilirubin &lt; 1.5 mg/dL (unless there is a known history of Gilberts&#xD;
                  Syndrome).&#xD;
&#xD;
               -  AST(SGOT)/ALT(SGPT) ≤2.5 X institutional upper limit of normal&#xD;
&#xD;
               -  Alkaline phosphatase &lt; 2.5 X upper limit of normal in the absence of liver or&#xD;
                  bone metastasis, or ≤ 5.0 × upper limit of normal range if bone or liver&#xD;
                  metastases&#xD;
&#xD;
               -  Creatinine clearance &gt;25 mL/min or creatinine &lt;1.5 mg/dL&#xD;
&#xD;
         11. HIV-positive patients on combination antiretroviral therapy are eligible if they have&#xD;
             been on ARVs for ≥6 months and undetectable viral loads.&#xD;
&#xD;
         12. Patients must not have documented evidence of acute hepatitis or have an active or&#xD;
             uncontrolled infection.&#xD;
&#xD;
         13. No other priormalignancy is allowed except for the following: adequately treated basal&#xD;
             cell or squamous cell skin cancer, in-situ cervical cancer, adequately treated Stage I&#xD;
             or II cancer from which the patient is currently in complete remission, or any other&#xD;
             cancer from which the patient has been disease-free for 5 years.&#xD;
&#xD;
         14. Ability to understand and the willingness to sign a written informed consent document&#xD;
             in English or a Spanish consent &quot;short form&quot;. If language other than English or&#xD;
             Spanish, then interpreter will be used to sign English consent form.&#xD;
&#xD;
         15. Patients must have &lt; Grade 2 pre-existing peripheral neuropathy (per CTCAE)&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Patients who have had palliative chemotherapy prior to entering the study &lt;12 months&#xD;
             from enrollment or those who have not recovered from adverse events due to agents&#xD;
             administered more than 4 weeks earlier.&#xD;
&#xD;
          2. Patients may not be receiving any other investigational agents or have received&#xD;
             immunotherapy.&#xD;
&#xD;
          3. Known EGFR or ALK mutated disease (molecular testing not required prior to study&#xD;
             entry)&#xD;
&#xD;
          4. History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to carboplatin, or nab-paclitaxel.&#xD;
&#xD;
          5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements.&#xD;
&#xD;
          6. Preexisting peripheral neuropathy of Grade 2, 3, or 4 (per Common Terminology Criteria&#xD;
             for Adverse Events v4.0)&#xD;
&#xD;
          7. Evidence of active brain metastases, including leptomeningeal involvement (prior&#xD;
             evidence of brain metastasis are permitted only if treated and stable and off therapy&#xD;
             for ≥ 2 weeks prior to signing Informed consent form. Magnetic Resonance Imaging of&#xD;
             the brain (or Computed Tomography scan w/contrast) is preferred for diagnosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>71 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rogerio Lilenbaum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>October 12, 2015</study_first_submitted>
  <study_first_submitted_qc>October 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2015</study_first_posted>
  <results_first_submitted>November 3, 2017</results_first_submitted>
  <results_first_submitted_qc>January 30, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 28, 2018</results_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Platinum-based Doublet Chemotherapy</title>
          <description>Carboplatin AUC 5 30 minute infusion IV on day 1&#xD;
Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle&#xD;
Carboplatin&#xD;
Nab-paclitaxel</description>
        </group>
        <group group_id="P2">
          <title>Single Agent Chemotherapy</title>
          <description>-Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle&#xD;
Nab-paclitaxel</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Platinum-based Doublet Chemotherapy</title>
          <description>Carboplatin AUC 5 30 minute infusion IV on day 1&#xD;
Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle&#xD;
Carboplatin&#xD;
Nab-paclitaxel</description>
        </group>
        <group group_id="B2">
          <title>Single Agent Chemotherapy</title>
          <description>-Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle&#xD;
Nab-paclitaxel</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment Failure-free Survival</title>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Platinum-based Doublet Chemotherapy</title>
            <description>Carboplatin AUC 5 30 minute infusion IV on day 1&#xD;
Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle&#xD;
Carboplatin&#xD;
Nab-paclitaxel</description>
          </group>
          <group group_id="O2">
            <title>Single Agent Chemotherapy</title>
            <description>-Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle&#xD;
Nab-paclitaxel</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Failure-free Survival</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate</title>
        <time_frame>start of treatment to disease progression/recurrence, up to 12 months</time_frame>
        <population>The study was terminated after only 3 patients were randomized and all 3 did not respond to treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Platinum-based Doublet Chemotherapy</title>
            <description>Carboplatin AUC 5 30 minute infusion IV on day 1&#xD;
Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle&#xD;
Carboplatin&#xD;
Nab-paclitaxel</description>
          </group>
          <group group_id="O2">
            <title>Single Agent Chemotherapy</title>
            <description>-Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle&#xD;
Nab-paclitaxel</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate</title>
          <population>The study was terminated after only 3 patients were randomized and all 3 did not respond to treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <time_frame>start of treatment to disease progression, up to 12 months</time_frame>
        <population>The study was terminated after only 3 patients were randomized and all 3 did not respond to treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Platinum-based Doublet Chemotherapy</title>
            <description>Carboplatin AUC 5 30 minute infusion IV on day 1&#xD;
Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle&#xD;
Carboplatin&#xD;
Nab-paclitaxel</description>
          </group>
          <group group_id="O2">
            <title>Single Agent Chemotherapy</title>
            <description>-Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle&#xD;
Nab-paclitaxel</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <population>The study was terminated after only 3 patients were randomized and all 3 did not respond to treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>Up to 12 months</time_frame>
        <population>The study was terminated after only 3 patients were randomized and all 3 did not respond to treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Platinum-based Doublet Chemotherapy</title>
            <description>Carboplatin AUC 5 30 minute infusion IV on day 1&#xD;
Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle&#xD;
Carboplatin&#xD;
Nab-paclitaxel</description>
          </group>
          <group group_id="O2">
            <title>Single Agent Chemotherapy</title>
            <description>-Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle&#xD;
Nab-paclitaxel</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <population>The study was terminated after only 3 patients were randomized and all 3 did not respond to treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Grade 3-5 Adverse Events</title>
        <description>Adverse events were characterized using Common Terminology Criteria for Adverse Events (CTCAE)</description>
        <time_frame>Up to week 13</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Platinum-based Doublet Chemotherapy</title>
            <description>Carboplatin AUC 5 30 minute infusion IV on day 1&#xD;
Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle&#xD;
Carboplatin&#xD;
Nab-paclitaxel</description>
          </group>
          <group group_id="O2">
            <title>Single Agent Chemotherapy</title>
            <description>-Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle&#xD;
Nab-paclitaxel</description>
          </group>
        </group_list>
        <measure>
          <title>Grade 3-5 Adverse Events</title>
          <description>Adverse events were characterized using Common Terminology Criteria for Adverse Events (CTCAE)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptom Assessment (Measured by FACT-L Symptom Assessment Scale)</title>
        <description>The FACT-L is measure of symptoms associated with lung cancer. The higher the score, the greater the symptoms. A maximum score of 136 could be obtained.</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Platinum-based Doublet Chemotherapy</title>
            <description>Carboplatin AUC 5 30 minute infusion IV on day 1&#xD;
Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle&#xD;
Carboplatin&#xD;
Nab-paclitaxel</description>
          </group>
          <group group_id="O2">
            <title>Single Agent Chemotherapy</title>
            <description>-Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle&#xD;
Nab-paclitaxel</description>
          </group>
        </group_list>
        <measure>
          <title>Symptom Assessment (Measured by FACT-L Symptom Assessment Scale)</title>
          <description>The FACT-L is measure of symptoms associated with lung cancer. The higher the score, the greater the symptoms. A maximum score of 136 could be obtained.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" spread="NA">Standard deviation is not calculated.</measurement>
                    <measurement group_id="O2" value="44" spread="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptom Assessment (Measured by FACT-L Symptom Assessment Scale)</title>
        <description>The higher the score, the greater the symptoms. The FACT-L is measure of symptoms associated with lung cancer. The higher the score, the greater the symptoms. A maximum score of 136 could be obtained. Symptoms were measured following 2 21-day cycles of chemotherapy.</description>
        <time_frame>week 6</time_frame>
        <population>Only 2 patients were assessed at this timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Platinum-based Doublet Chemotherapy</title>
            <description>Carboplatin AUC 5 30 minute infusion IV on day 1&#xD;
Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle&#xD;
Carboplatin&#xD;
Nab-paclitaxel</description>
          </group>
          <group group_id="O2">
            <title>Single Agent Chemotherapy</title>
            <description>-Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle&#xD;
Nab-paclitaxel</description>
          </group>
        </group_list>
        <measure>
          <title>Symptom Assessment (Measured by FACT-L Symptom Assessment Scale)</title>
          <description>The higher the score, the greater the symptoms. The FACT-L is measure of symptoms associated with lung cancer. The higher the score, the greater the symptoms. A maximum score of 136 could be obtained. Symptoms were measured following 2 21-day cycles of chemotherapy.</description>
          <population>Only 2 patients were assessed at this timepoint.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="60.5" spread="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptom Assessment (Measured by FACT-L Symptom Assessment Scale)</title>
        <description>The FACT-L is measure of symptoms associated with lung cancer. The higher the score, the greater the symptoms. Symptoms were measured following 4 21-day cycles of chemotherapy.</description>
        <time_frame>week 12</time_frame>
        <population>The study was terminated after only 3 patients were randomized and all 3 did not respond to treatment, these data were not collected at week 12</population>
        <group_list>
          <group group_id="O1">
            <title>Platinum-based Doublet Chemotherapy</title>
            <description>Carboplatin AUC 5 30 minute infusion IV on day 1&#xD;
Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle&#xD;
Carboplatin&#xD;
Nab-paclitaxel</description>
          </group>
          <group group_id="O2">
            <title>Single Agent Chemotherapy</title>
            <description>-Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle&#xD;
Nab-paclitaxel</description>
          </group>
        </group_list>
        <measure>
          <title>Symptom Assessment (Measured by FACT-L Symptom Assessment Scale)</title>
          <description>The FACT-L is measure of symptoms associated with lung cancer. The higher the score, the greater the symptoms. Symptoms were measured following 4 21-day cycles of chemotherapy.</description>
          <population>The study was terminated after only 3 patients were randomized and all 3 did not respond to treatment, these data were not collected at week 12</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Single Agent Chemotherapy</title>
          <description>-Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle&#xD;
Nab-paclitaxel</description>
        </group>
        <group group_id="E2">
          <title>Platinum-based Doublet Chemotherapy</title>
          <description>Carboplatin AUC 5 30 minute infusion IV on day 1&#xD;
Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle&#xD;
Carboplatin&#xD;
Nab-paclitaxel</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Blood disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Creatinine Increase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Edema Limbs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rogerio C. Lilenbaum, MD, Professor of Medicine (Medical Oncology); Chief Medical Officer of Smilow</name_or_title>
      <organization>Yale University</organization>
      <phone>(203) 200-5864</phone>
      <email>rogerio.lilenbaum@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

